Datar Cancer Genetics Receives US FDA Clearance for CellDx-Tissue Comprehensive Genomic Profiling Assay
核心洞察
Datar Cancer Genetics (搜索) received US FDA (搜索) clearance for CellDx-Tissue (搜索), a comprehensive genomic profiling assay that analyzes 517 cancer-associated genes using DNA and RNA from solid tumor tissue samples.
The assay provides information on somatic variants, gene amplifications, and specific gene fusions involving ALK (搜索), RET (搜索), and ROS1 (搜索) to support personalized treatment decisions for solid tumor patients.
This regulatory milestone strengthens DCG's position in precision oncology and enables broader collaboration with international clinical and biopharmaceutical partners on a common regulatory platform.
Datar Cancer Genetics (搜索) (DCG), a global precision oncology company, announced that its tissue-based comprehensive genomic profiling assay CellDx-Tissue (搜索) has received clearance from the US Food and Drug Administration. The regulatory approval represents a significant milestone for the India-based company's expansion into global markets and strengthens its position in delivering precision oncology solutions to oncologists worldwide.
Comprehensive Genomic Analysis Platform
CellDx-Tissue (搜索) is a qualitative in vitro diagnostic test that employs targeted Next-Generation Sequencing of DNA and RNA isolated from formalin-fixed paraffin-embedded tumor tissue samples from patients diagnosed with solid tumors. The assay analyzes 517 cancer-associated genes and provides comprehensive genomic information including somatic single nucleotide variants, small insertions and deletions, ERBB2 (搜索) gene amplification, and gene fusions involving ALK (搜索), RET (搜索) and ROS1 (搜索).
The dual-analyte DNA and RNA workflow enables detection of gene fusions through RNA-level evidence, providing oncologists with detailed molecular characterization of tumors to guide treatment decisions. The assay is performed as a single-site test at Datar Cancer Genetics (搜索)' CAP- and CLIA-accredited laboratory.
Clinical Significance and Market Impact
Comprehensive genomic profiling has become a central component of clinical management for solid tumors, supporting clinicians in characterizing tumor genomic alterations across a broad spectrum of cancer types. The US FDA (搜索) clearance process spans analytical, clinical, and information technology domains, representing a rigorous validation of the platform's clinical utility.
"This US FDA (搜索) clearance for CellDx-Tissue (搜索) adds gold-standard regulatory endorsement to an important solution offered by DCG," said Dr. Vineet Datta, Senior Director – Global Strategy and Business Development. "CellDx-Tissue bridges the gap between genomic complexity and clinical decision-making, offering patients wider options in an era of rapidly evolving therapies."
Regulatory Foundation for Global Expansion
The clearance consolidates DCG's position to engage with international clinical, academic and biopharmaceutical partners on a common regulatory footing for clinical management support, translational research, and biomarker development programs. This regulatory milestone complements the company's earlier US FDA (搜索) Breakthrough Device Designations for its liquid biopsy platforms.
Dr. Darshana Patil, Senior Director – Group Medical Affairs, emphasized the validation aspect: "US FDA (搜索) clearance of our tissue-based genomic panel is a substantive validation of our science and quality systems. It enables us to support oncologists with robust, standardised genomic information to guide complex treatment decisions."
Platform Development and Quality Systems
The clearance reflects the scientific rigor and clinical orientation that DCG's development teams have brought to the CellDx-Tissue (搜索) platform. Dr. Dadasaheb Akolkar, Director – Research & Innovation, noted: "This clearance reflects the consistency, rigor and clinical orientation our scientific and quality teams have brought to the development of CellDx-Tissue platform. We look forward to extending our transformational precision oncology solutions to cancer patients across global markets."
Datar Cancer Genetics (搜索) operates as an AI-driven precision oncology company with UKAS-, CAP- and CLIA-accredited laboratories and maintains a presence across the United Kingdom, the European Union, the United States, the Gulf Cooperation Council and Asia. The company partners with clinicians and cancer centers worldwide to enable personalized cancer care for patients with solid organ cancers through advanced cancer diagnostics, including non-invasive liquid biopsy and tissue-based multi-omic solutions.